-
Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative Choices
Friday, February 20, 2015 - 2:10pm | 329In a report published Friday, Jefferies analyst Jeffrey Holford named AbbVie Inc (NASDAQ: ABBV) as a "Top Global Pick" in the Pharmaceutical space, replacing Pfizer Inc. (NYSE: PFE). Holford added that shares have seen significant pressure since mid-December as the initial...
-
Jefferies Analyst Says AbbVie Hepatitis C Price-War Fears Overblown
Monday, February 9, 2015 - 12:46pm | 377AbbVie Inc (NYSE: ABBV) shares are likely to rally with the expected near-term release of new data on two key drug candidates, an analyst said Monday. Jefferies' Jeffrey Holford maintained a Buy rating and $80 target on the company. AbbVie's recent selloff on fears of a price war...
-
A Pair Trade With Eli Lilly And Johnson & Johnson? Goldman Just Explained Why It's A Solid Idea
Thursday, January 15, 2015 - 6:40pm | 288In a recent report, Goldman Sachs analysts provided an idea for a pair trade with Eli Lilly and Co (NYSE: LLY) and Johnson & Johnson (NYSE: JNJ). The firm expects to see Eli Lilly deliver better results in 2015 than Johnson & Johnson. Eli Lilly Goldman upgraded Eli Lilly’...
-
Deutsche Bank, Stifel Differ On Outlook For Eli Lilly
Thursday, January 8, 2015 - 1:46pm | 284Deutsche Bank and Stifel took differing positions on Eli Lilly and Co (NYSE: LLY) Thursday. Analyst Gregg Gilbert at Deutsche Bank downgraded the stock from Buy to Hold and maintained a $75 price target. Gilbert felt the stock had performed well in 2014, but little upside remained. “...
-
Jefferies Raises Zoetis Price Target, Says Consolidation Continues To Look Likely
Wednesday, November 26, 2014 - 10:03am | 207Jeffrey Holford of Jefferies speculates that consolidation "continues to look likely" for Zoetis Inc (NYSE: ZTS) in 2015. According to Holford, Zoetis' 2015 revenue guidance of $4.85 billion to $4.95 billion and earnings per share of $1.61 to $1.68 were both below expectations but...
-
UPDATE: Jefferies Lowers PT on Zoetis on Challenges Ahead
Friday, July 12, 2013 - 8:56am | 119In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Zoetis (NYSE: ZTS), but lowered the price target from $40.00 to 39.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income...
-
UPDATE: Jefferies Downgrades Pfizer on Challenges Ahead
Friday, July 12, 2013 - 8:54am | 122In a report published Friday, Jefferies analyst Jeffrey Holford downgraded the rating on Pfizer (NYSE: PFE) from Buy to Hold, and lowered the price target from $32.00 to $30.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been...
-
UPDATE: Jefferies Lowers PT on Merck on Challenges Ahead
Friday, July 12, 2013 - 8:53am | 119In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck (NYSE: MRK), but lowered the price target from $56.00 to $54.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been driven by income...
-
UPDATE: Jefferies Raises PT on Johnson & Johnson on Challenges Ahead
Friday, July 12, 2013 - 8:49am | 123In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), and raised the price target from $91.00 to $92.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been...
-
UPDATE: Jefferies Downgrades Bristol-Myers Squibb on Challenges Ahead
Friday, July 12, 2013 - 8:47am | 122In a report published Friday, Jefferies analyst Jeffrey Holford downgraded Bristol-Myers Squibb (NYSE: BMY) from Buy to Hold, and lowered the price target from $53.00 to $49.00. In the report, Jefferies noted, “Rising rate expectations had the expected impact on the sector, which has been...
-
UPDATE: Jefferies Lowers PT on Pfizer Following Global Pharma Review
Friday, June 7, 2013 - 12:32pm | 100In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Pfizer (NYSE: PFE), but lowered the price target from $33.00 to $32.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in...
-
UPDATE: Jefferies Raises PT on Merck & Co. Following Global Pharma Review
Friday, June 7, 2013 - 12:32pm | 102In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Merck & Co. (NYSE: MRK), and raised the price target from $54.00 to $56.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection...
-
UPDATE: Jefferies Lowers PT on Johnson & Johnson Following Global Pharma Review
Friday, June 7, 2013 - 12:31pm | 102In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Hold rating on Johnson & Johnson (NYSE: JNJ), but lowered the price target from $97.00 to $91.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth...
-
UPDATE: Jefferies Lowers PT on Bristol-Myers Squibb Following Global Pharma Review
Friday, June 7, 2013 - 12:30pm | 104In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on Bristol-Myers Squibb Co. (NYSE: BMY), but lowered the price target from $53.50 to $53.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth...
-
UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential
Friday, June 7, 2013 - 12:30pm | 100In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential...